- In Canada and Brazil, ETST is lab testing three new cannabidiol formulations, developing two more CBD products and conducting studies on its Hygee device for women
- In the U.S., it is researching CBD’s impact on breast cancer and immune cells
- ETST is focused on the development of innovative products to reach its goal of becoming a world leader in the CBD space, with three new CBD formulas being developed under a provisory patent
Earth Science Tech, Inc. (OTC: ETST) is testing in Canada and Brazil a diverse mix of cannabidiol (CBD) formulations, including a superfood formula (http://nnw.fm/0gc1E). It is also conducting pre-launch lab studies of a medical device scheduled to be marketed internationally (http://nnw.fm/g4vqP).
ETST is a biotech company based in Doral, Florida, marketing and developing CBD products for the pharmaceutical and nutraceutical fields. The company manufactures, markets and distributes its own cannabinoid products, including capsules and oils. ETST has revamped its line of CBD products and will extend its line of raw dark chocolates with three new flavors in conjunction with joint venture partner Karmavore Superfoods. An anticipated launch is planned for the third quarter of 2018 (http://nnw.fm/HD4ga).
In Canada, the company is testing three new CBD IP formulations. They include a neuron protector and a breast protector. R&D is being conducted by the Centre de Developpement bioalimentaire du Quebec (CDBQ) or Quebec Agrifood Innovation Center (QAIC). An additional formulation will include a natural protective agent that will extend shelf life. A third product is a superfood that includes a mix of hemp oil and a highly potent antioxidant. In Quebec, the company is also clinically testing its Hygee MSN-2 medical device for detection of sexually transmitted infections (STIs) in women at the Clinique Santé Amitié.
ETST is developing two new products in Brazil through a joint venture with Bionatus Laboratrio Botnico of Brazil and its Canadian division, Bionatus Botanical Laboratories, Inc. The products are Propovit, enriched with ETST hemp oil, and a reformulation of Bionatus’ product featuring CBD.
In the U.S., it is conducting studies with the University of Central Oklahoma of high grade full spectrum CBD on breast cancer and immune cells.
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc., is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. ETST also recently formed subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company that provides ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]